Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRVBiotechnology
+$0.05 today
- Market cap
- $66.94M
- Beta
- 1.91
- P/E (TTM)
- -0.8
- EPS (TTM)
- -$2.00
Volume 0.61M
Average 0.60M
ACRV EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Acrivon Therapeutics, Inc. Common StockNASDAQ: ACRV
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$18.66M, compared with -$19.37M a year earlier. Trailing-twelve-month EBITDA was -$82.08M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +3.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.66M+24.9% QoQ
- Last fiscal yearDec 2025
- -$76.55M+3.8% YoY
- LTMMar 2026
- -$82.08M+0.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +3.7% | +100.0% | +96.3 pp |
| 1 year | +3.8% | +100.0% | +96.2 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (76.55M) USD
- Year-over-year change
- +3.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (76.55M) | +3.8% |
| FY2024 | 2024-12-31 | (79.55M) | -32.9% |
| FY2023 | 2023-12-31 | (59.85M) | -94.3% |
| FY2022 | 2022-12-31 | (30.8M) | -90.1% |
| FY2021 | 2021-12-31 | (16.21M) | — |
EBITDA vs competitors
How ACRV compares with its peers on the latest reported figures
- ACRV's LTM Mar 2026 EBITDA of -$82.08M is the 8th highest of the 10 companies compared; the peer median is -$62.31M.
- Its year-over-year change of +0.7% is the 5th highest of 10, against a peer median of +0.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.3M | +203.4% | — | 18.5% | |
| LTM Mar 2026 | -$39.25M | -164.0% | — | — | |
| LTM Mar 2026 | -$46.12M | +63.6% | — | — | |
| LTM Mar 2026 | -$58.88M | -297.6% | — | — | |
CBUSCibus, Inc. | LTM Mar 2026 | -$62.31M | +76.4% | — | 1453.8% |
| LTM Mar 2026 | -$68.69M | -10.6% | — | 36154.2% | |
| LTM Mar 2026 | -$78.19M | +0.2% | — | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$82.08M | +0.7% | — | — |
| LTM Mar 2026 | -$104.13M | -8.2% | — | — | |
| LTM Mar 2026 | -$118.65M | +4.8% | — | 1298.7% | |
| Peer median (excluding ACRV) | -$62.31M | +0.2% | — | 1376.3% | |
Competitors are the stored peer set for ACRV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 536K | 1.01M | 1.36M |
| Gross Profit | 0 | 0 | (536K) | (1.01M) | (1.36M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 13.72M | 23.95M | 45.49M | 63.99M | 59.99M |
| Selling, General & Admin | 2.47M | 8.71M | 21.21M | 25.21M | 24.12M |
| Operating Expenses | 16.18M | 32.66M | 66.7M | 88.19M | 82.76M |
| Depreciation & Amortization | 37K | 364K | 536K | 1.01M | 1.36M |
| EBITDA | (16.21M) | (30.8M) | (59.85M) | (79.55M) | (76.55M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (16.18M) | (32.66M) | (67.24M) | (89.2M) | (84.11M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 7.04M | 9.2M | 6.48M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (59K) | 1.49M | 6.85M | 8.64M | 6.21M |
| Income Before Tax | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (16.24M) | (31.17M) | (60.39M) | (80.56M) | (77.91M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.26) | (1.42) | (2.74) | (2.10) | (2.02) |
| EPS (Diluted) | (1.26) | (1.42) | (2.74) | (2.10) | (2.02) |
| Weighted Avg Shares | 12.91M | 21.92M | 22.08M | 38.3M | 38.51M |
| Weighted Avg Shares (Diluted) | 12.91M | 21.92M | 22.08M | 38.3M | 38.51M |
Acrivon Therapeutics, Inc. Common Stock
NASDAQ:ACRV
Intrinsic Alpha fair value
Locked
Current Price
$1.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.